Study examines access to 121 drugs approved since 2015 by EU regulator

Medicines generally blocked on basis of price as Ipha says delay ‘unacceptably long’

Spinraza is the latest in a series of controversial drugs that have put Ireland’s unique approval system in the spotlight

Cantillon: Patients have one shot at treatment but what if it is deemed too expensive?

Row between industry and body that advises the HSE over access to market for new medicines

Labour TD criticises selective provision of drug to women caught up in CervicalCheck controversy

‘It’s also important for researchers to hear what patients want from new drugs’

‘You have to ask why other countries have been happy with the clinical evidence but not here’ - mother of girl (10)

HSE representatives defend process for deciding which drugs to reimburse

Healthcare companies gave €30 million to hospitals, medical staff in 2016, says Minister

Kuvan is the only drug treatment for rare metabolic ‘heel prick test’ disorder

HSE decides against approving Translarna for reimbursement under drugs schemes

Department says it is considering three medicines for approval

Manufacturer accuses HSE of deviating from approvals processes by blocking Perjeta

More patients are switching to Long-Term Illness scheme to avoid paying charge

Over 20 emphysema sufferers to see use of ‘life changing’ Respreeza finish in two weeks

Over 20 sufferers are given Respreeza reprieve while talks continue on approving the treatment

Nellie Lannen (22 months) has condition causing muscle wastage, impaired breathing

US pharma Vertex in talks with HSE to reduce high price of cystic fibrosis drug

Negotiations with manufacturer ongoing as Harris accuses Vertex of trying to ‘extort’ taxpayers

Alpha-1 deficiency is a hereditary condition that has an “unusually high” prevalence here

Health spending in one area cannot come at expense of another

Orkambi had been ‘considered unjustifiably expensive and not sufficiently cost effective’

Taoiseach says meetings are under way with pharmaceutical firm over cost of Orkambi

Study finds the use of the ‘wonder drug’ would cost €21m over a five-year period

A third of patients with advanced renal cell carcinoma were alive five years after treatment

#YesOrkambi drive launched in support of approval for €160,000 per patient medicine

Melanoma patients told State to cover Pembro, while CF drug Orkambi ‘too expensive’

Inside Politics: Government suffers its first defeat on a vote

CF campaigner Orla Tinsley says decision disappointing as trials showed drug works

Pembrolizumab to be included in drugs scheme three months after economic approval

Price talks urged between Government and maker on €160,000 per patient medicine

Bristol-Myers Squibb allows compassionate access to nivolumab after appeal by Harris

Politicians are the least qualified to make call on treatment options

Numerous controversies over huge costs of drugs have erupted. What price do we put on life?

Living with PKU: Families call for genetic disorder drug that is available in UK as highly restricted diet to hard to follow

Orkambi has been described as a ‘game changer’ by health campaigners

Micheál Martin says cystic fibrosis patients will need help to pay for new drug, Orkambi

HSE says it cannot afford Orkambi which will reportedly cost €160,000 per patient per year

Initiative aimed at cost-efficient prescribing that could potentially save €15m on drugs bill